Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics
Bupropion is an antidepressant of the aminoketone class that is chemically unrelated to any other known antidepressant agent. In the treatment of major depressive disorder (MDD), bupropion has shown comparable therapeutic efficacy to selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs). Bupropion effectiveness in treating co-morbid fatigue, hypersomnia, anhedonia, and mild to moderate anxiety symptoms (contrary to common clinician beliefs) associated with MDD is well documented. It is generally well tolerated with minimal undesirable side effects associated with antidepressants, such as sexual dysfunction and weight gain. Bupropion has shown effectiveness in augmentation as well as in switching strategies of antidepressant medications. Due to its favorable side-effect profile, bupropion has been used in the treatment of geriatric depression with good therapeutic efficacy and health outcome measurements. Bupropion has also shown usefulness as a smoking cessation agent and in treating depression in patients with medical co-morbidities such as asthma and HIV. Limitations of use include individuals at risk for seizures and patients with eating disorders.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
As a new contributor, my experience publishing our article in Genetics and Epigenetics was extremely positive. The reviewing process was prompt and fair (four reviewers examined our review article!) and then, the editorial office was very helpful by regularly updating me on the progression of the publication process. I strongly recommend the journal to my colleagues in the field and hope that the journal will grow up and gain the notoriety it deserves in our ...